QED Therapeutics Revenue and Competitors

Claim your profile

$65M

Total Funding

Estimated Revenue & Valuation

QED Therapeutics's estimated annual revenue is currently $5.7M per year.(i)
QED Therapeutics received $65.0M in venture funding in January 2018.
QED Therapeutics's estimated revenue per employee is $77,500
QED Therapeutics's total funding is $65M.

Employee Data

QED Therapeutics has 74 Employees.(i)
QED Therapeutics grew their employee count by -11% last year.

QED Therapeutics Competitors & Alternatives

Competitor Name	Revenue	Number of Employees	Employee Growth	Total Funding	Valuation
#1 DiaCarta	$4.7M	61	9%	$53M	N/A
#2 Mission Bio	$34.3M	177	17%	$110M	N/A
#3 Geron Corporati...	$0.4M	273	5%	$236.7M	N/A
#4 Mindstrong	$34.5M	178	-5%	$160M	N/A
#5 SafeTraces	$3.7M	24	20%	N/A	N/A
#6 Rigel Pharmaceu...	$147.3M	321	2%	$192.5M	N/A
#7 Althea Technolo...	$17.5M	113	-3%	$24.1M	N/A
#8 Kumquat Bioscie...	$2.7M	43	79%	N/A	N/A
#9 Kriya Therapeut...	$34.1M	220	100%	N/A	N/A
#10 INOVA Diagnosti...	$47.1M	304	-3%	N/A	N/A

Show More Biotech Companies

What Is QED Therapeutics?

QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Our lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. We plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.

keywords:N/A

$65M

Total Funding

Number of Employees

$5.7M

Revenue (est)

-11%

Employee Growth %

N/A

Valuation

N/A

Accelerator